A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects

Trial Profile

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs PRO 140 (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Registrational; Therapeutic Use
  • Sponsors CytoDyn
  • Most Recent Events

    • 13 Oct 2017 Planned number of patients changed from 30 to 50, according to a CytoDyn Inc. media release.
    • 13 Oct 2017 According to a CytoDyn Inc. media release, The FDA accepted the 40 patients currently enrolled as evaluable and further agreed that the Data Monitoring Committee can conduct an interim efficacy analysis of primary endpoint. The FDA also confirmed that 50 patients will be required for the completion of this trial and agreed to allow more flexibility in the enrollment criteria for the remaining 10 patients.
    • 05 Sep 2017 Planned End Date changed from 1 Aug 2019 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top